A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma



Status:Terminated
Conditions:Prostate Cancer, Cancer, Cancer, Cancer, Cancer, Renal Impairment / Chronic Kidney Disease, Urology
Therapuetic Areas:Nephrology / Urology, Oncology
Healthy:No
Age Range:18 - Any
Updated:7/27/2018
Start Date:May 2015
End Date:November 3, 2017

Use our guide to learn which trials are right for you!

A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

This is a study to determine the clinical benefit (how well the drug works), safety, and
tolerability of combining varlilumab and sunitinib. The study will enroll patients with
metastatic clear cell renal cell carcinoma.

Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found on
certain immune cells and may act to promote anti-tumor effects.

Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) some of
which play a role in tumor growth and progression of cancer.

This study will evaluate the safety, tolerability and efficacy of the anti-CD27 antibody
varlilumab in combination with sunitinib.

Eligible patients that enroll in the dose escalation portion of the study will be assigned to
one of three dose levels of varlilumab in combination with 50 mg of sunitinib. The first
phase of the study will test the safety profile of the combination and determine which dose
of varlilumab will be studied in Phase ll* of the overall study.

*Note: This Study was terminated prior to initiation of Phase II.

All patients enrolled in the study will be closely monitored to determine if there is a
response to the treatment as well as for any side effects that may occur.

Inclusion Criteria:

1. Histologically confirmed diagnosis of predominant clear cell renal cell carcinoma.

2. Advanced metastatic disease

3. Documented progressive disease based on radiographic, clinical or pathologic
assessment during or subsequent to last therapy.

4. For Phase l, no more than 3 prior anticancer regimens (IL-2 or interferon do not count
towards the total).

5. Measurable (target) disease.

6. Life expectancy ≥ 12 weeks.

7. If of childbearing potential (male or female), agrees to practice an effective form of
contraception during study treatment and for at least 70 days following last treatment
dose.

8. Must have available tumor tissue and consent to biopsy while on study.

Exclusion Criteria:

1. Prior therapy with an anti-CD27 antibody.

2. Previous treatment with sunitinib.

3. Use of any experimental immunotherapy.

4. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to
the planned start of study treatment.

5. Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or
radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of
study treatment.

6. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within
2 weeks prior to first dose of study treatment.

7. Other prior malignancy, except for adequately treated basal or squamous cell skin
cancer or in situ cancers; or any other cancer from which the patient has been
disease-free for at least 3 years.

8. Active, untreated central nervous system metastases.

9. Active autoimmune disease or a documented history of autoimmune disease.

10. Active diverticulitis.

11. Significant cardiovascular disease including CHF or poorly controlled hypertension.

12. Impairment of gastrointestinal function or gastrointestinal disease that may alter the
absorption of sunitinib.
We found this trial at
9
sites
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Guru Sonpavde, MD
Phone: 205-934-0337
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Principal Investigator: Elisabeth Heath, MD
Phone: 313-576-8715
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Principal Investigator: Che-Kai Tsao, MD
Phone: 212-659-5412
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
Omaha, Nebraska 68114
Principal Investigator: Ralph J Hauke, MD
Phone: 402-334-4773
?
mi
from
Omaha, NE
Click here to add this to my saved trials
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Jean Hoffman-Censits, MD
Phone: 215-503-2703
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4501 X St
Sacramento, California 95817
(916) 734-5800
Principal Investigator: Chong-xian Pan, MD, PhD
Phone: 916-734-8291
UC Davis Comprehensive Cancer Center When faced with cancer, you want the best hope for...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Washington, District of Columbia 20037
?
mi
from
Washington,
Click here to add this to my saved trials